Results 21 to 30 of about 136,022 (256)
Nature Communications, 2020 Antibody-drug conjugates targeting high expression receptors can suffer from poor tumour penetration. Here, the authors use unconjugated antibody to improve the penetration of an antibody-dye conjugate in a clinical study, supporting further clinical ...
Guolan Lu +8 more
doaj +1 more source
Antibody–siRNA conjugates (ARC): Emerging siRNA drug formulation
Medicine in Drug Discovery, 2022 Antibody–drug conjugates (ADC) utilizing the targeting properties of antibodies and therapeutic effects of drugs have emerged a rapid development in recent years.
Weiran Cao +9 more
doaj +1 more source
A Non-Covalent Antibody Complex for the Delivery of anti-cancer drugs [PDF]
, 2019 Antibody drug conjugates (ADCs), which are obtained by coupling a potent cytotoxic agent to a monoclonal antibody (mAb), are traditionally bound in a random way to lysine or cysteine residues, with the final product's heterogeneity having an important ...
Grigoletto, Antonella +5 more
core +1 more source
Emerging Pharmacotherapy for Relapsed or Refractory Hodgkins Lymphoma: Focus on Brentuximab Vedotin
Clinical Medicine Insights: Oncology, 2012 Hodgkins lymphoma (HL) which has relapsed post or is refractory to autologous bone marrow transplant presents an ongoing treatment challenge. Development of monoclonal antibodies (mAb) for the treatment of HL has aimed to replicate the success of mAb ...
Michelle Furtado, Simon Rule
doaj +1 more source
Molecules, 2023 Immunogenicity is a major issue associated with the PK, efficacy, and safety evaluation of therapeutic protein products during pre-clinical and clinical studies. A multi-tiered approach consisting of screening, confirmatory, and titration assays has been
Tingting Liu +12 more
doaj +1 more source
Potential novel therapy targets in neuroendocrine carcinomas of the breast [PDF]
, 2018 Neuroendocrine carcinoma (NEC) of the breast is a rare, special type of breast cancer, reportedly constituting 2% to 5% of all breast cancers. Although breast NEC does not have a specific targeted therapy, several new targeted therapies based on specific
Contreras, Elma +7 more
core +2 more sources
Novel method for screening functional antibody with comprehensive analysis of its immunoliposome
Scientific Reports, 2021 Development of monoclonal antibody is critical for targeted drug delivery because its characteristics determine improved therapeutic efficacy and reduced side-effect.
Shusei Hamamichi +4 more
doaj +1 more source
HER2-targeting Peptide Drug Conjugate with Better Penetrability for Effective Breast Cancer Therapy
BIO Integration, 2023 Antibody-drug conjugates (ADCs) have the following advantages: target specificity; wide therapeutic index; and prolonged circulation half-life. A key limitation of ADCs, however, is the large size (~150 kDa), which markedly slows diffusion through the ...
Yixia Liang +9 more
doaj +1 more source
Strain prioritization and genome mining for enediyne natural products [PDF]
, 2016 The enediyne family of natural products has had a profound impact on modern chemistry, biology, and medicine, and yet only 11 enediynes have been structurally characterized to date.
Ben Shen +18 more
core +2 more sources
Site-selective protein modification via disulfide rebridging for fast tetrazine/trans-cyclooctene bioconjugation [PDF]
, 2020 An inverse electron demand Diels–Alder reaction between tetrazine and trans-cyclooctene (TCO) holds great promise for protein modification and manipulation.
Chudasama, V. +6 more
core +1 more source